alleging Muddy Waters and others released false and misleading information to lower the value of St. Jude's stock so they could profit through a short-selling scheme. The FDA, in partnership with the Department of Homeland Security, is …
St. Jude’s stock closed down nearly 4 percent on Thursday. Abbot Laboratories made a $25 billion bid for St. Jude back in April. Thanks to these vulnerabilities, that deal could be in peril, according to Bloomberg. MedSec’s CEO Justine …
St. Jude Medical says that the report, which used "false and misleading tactics" for scaremongering purposes, was intentionally designed for the sake of a short-selling scheme. These schemes involve investors which sell stock if they …
On August 25, Muddy Waters investments announced it had bet against St. Jude stock in a report that described two cybersecurity vulnerabilities in popular St. Jude pacemakers. St. Jude Medical has said that research was fraudulent. …
St. Jude stock was selling for $79.40 a share on Tuesday afternoon ... Maria Castellucci covers safety and quality topics for Modern Healthcare’s website and print edition. Castellucci is a graduate of Columbia College Chicago and started …
According to the complaint the plaintiff alleges on behalf of purchasers of common stock of St Jude Medical Inc …
Chicago-headquartered Abbott announced Thursday it is acquiring Minnesota-based St. Jude Medical in a cash-and-stock deal worth about $25 billion. The acquisition, subject to regulatory approvals, will strengthen Abbott's position in the …
Rather than inform the company, MedSec did a deal with a Wall Street firm to short-sell St Jude stock and then go public with the news. "While we would have preferred the opportunity to review a detailed account of the information, based on …
Abbott Laboratories will spend $25 billion to buy St. Jude Medical Inc. in a cash-stock deal that aims to strengthen the medical device maker's stake in cardiovascular care. Shares of North Chicago, Illinois-based Abbott plunged, while St.
Investors initially are not so enamored with the acquisition. Abbott's stock was down nearly 6 percent in early afternoon trading to just over $41 a share, while St. Jude rose more than 25 percent to nearly $79 a share. Abbott's stock-and …